Cubist Pharmaceuticals (CBST) agrees to acquire Adolor (ADLR) for ~$190M in cash, or...

Cubist Pharmaceuticals (CBST) agrees to acquire Adolor (ADLR) for ~$190M in cash, or $4.25/share, and will make an additional contigent payment of up to $4.25/share for certain milestones related to Adolor's ADL5945, a potential treatment for chronic opioid induced constipation. ADLR +134.9% premarket.

From other sites
Comments (2)
  • David Greene
    , contributor
    Comments (141) | Send Message
    The buyout of ADLR bodes well for other small biotechs that have good technology that would be a fit in a better-capitalized company's portfolio of promising pharmaceuticals.
    24 Oct 2011, 08:43 AM Reply Like
  • ouroboros12321
    , contributor
    Comments (2) | Send Message
    So when you see a story like this, how do you purchase on the upswing? For example, I tried to buy shares of ADLR in Scottrade's premarket @ $41 but have had no luck.
    I have tried to research this but have found no good information so far. Any suggestions?
    By the way, I'm loving this website.
    24 Oct 2011, 10:13 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs